Simultaneous quantitation of topoisomerase II α and β isoform mRNAs in lung tumor cells and normal and malignant lung tissue

Laboratory Investigation

Volumn 80, Issue 6, 2000, Pages 787-795

  Mirski, Shelagh E L ^a   Voskoglou Nomikos, Theodora ^a   Young, Leah C ^a   Deeley, Roger G ^a   Campling, Barbara G ^a   Gerlach, James H ^a   Cole, Susan P C ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); MESSENGER RNA;

ADENOCARCINOMA; ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME ANALYSIS; ENZYME ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LUNG TUMOR; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL; TUMOR CELL;

EID: 0033933780     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1038/labinvest.3780083     Document Type: Article

References (39)

1. Campling BG, Baer KA, Gerlach JH, Lam YM, Cole SP, and Mirski SEL (1997a). Topoisomerase II levels and drug response in small cell lung cancer. Int J Oncol 10:885-893.
2. Campling BG, Haworth AC, Baker HM, Greer DL, Holden JJ, Bradley EC, Pym J, and Dexter DF (1992). Establishment and characterization of a panel of human lung cancer cell lines. Cancer 69:2064-2074.
3. Campling BG, Young LC, Baer KA, Lam YM, Deeley RG, Cole SPC, and Gerlach JH (1997b). Expression of the MRP and MDR1 multidrug resistance genes in small cell lung cancer. Clin Cancer Res 3:115-122.
4. Cornarotti M, Tinelli S, Willmore E, Zunino F, Fisher LM, Austin CA, and Capranico G (1996). Drug sensitivity and sequence specificity of human recombinant DNA topoisomerase IIα (p170) and IIβ (p180). Mol Pharmacol 50:1463-1471.
5. Davies SL, Bergh J, Harris AL, and Hickson ID (1997). Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors. Br J Cancer 75:816-821.
6. Dingemans AM, Witlox MA, Stallaert RA, van der Valk P, Postmus PE, and Giaccone G (1999). Expression of DNA topoisomerase IIα and topoisomerase IIβ genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 5:2048-2058.
7. Dingemans AM, Pinedo HM, and Giaccone G (1998). Clinical resistance to topoisomerase-targeted drugs. Biochim Biophys Acta 1400:275-288.
8. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, and Mirabelli CK (1989). Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28:8154-8160.
9. Fattman CL, Allan WP, Hasinoff BB, and Yalowich JC (1996). Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells. Biochem Pharmacol 52:635-642.
10. Galimberti S, Marchetti A, Buttitta F, Carnicelli V, Pellegrini S, Bevilacqua G, and Petrini M (1998). Multidrug resistance related genes and p53 expression in human non small cell lung cancer. Anticancer Res 18:2973-2976.
11. Giaccone G, Gazdar AF, Beck H, Zunino F, and Capranico G (1992). Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 52:1666-1674,
12. Giaccone G, van Ark-Otte J, Scagliotti GV, Capranico G, van der Valk P, Rubio GJ, Dalesio O, Lopez R, Zunino F, Walboomers J, and Pinedo HM (1995). Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim Biophys Acta 1264:337-346.
13. Guinee DG, Holden JA, Benfield JR, Woodward ML, Przygodzki RM, Fishback NF, Koss MN, and Travis WD (1996). Comparison of DNA topoisomerase IIα expression in small cell and nonsmall carcinoma of the lung. In search of a mechanism of chemotherapeutic response. Cancer 78:729-735.
14. Hasegawa T, Isobe K-I, Nakashima I, and Shimokata K (1993). Higher expression of topoisomerase II in lung cancers than normal lung tissues: Different expression pattern from topoisomerase I. Biochem Biophys Res Commun 195:409-414.
15. Hochhauser D, Stanway CA, Harris AL, and Hickson ID (1992). Cloning and characterization of the 5′-flanking region of the human topoisomerase IIα gene. J Biol Chem 267: 18961-18965.
16. Holden JA, Rolfson DH, and Wittwer CT (1992). The distribution of immunoreactive topoisomerase II protein in human tissues and neoplasms. Oncol Res 4:157-166.
17. Houlbrook S, Harris AL, Carmichael J, and Stratford IJ (1996). Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell lines. Anticancer Res 16:1603-1610.
18. Kasahara K, Fujiwara Y, Sugimoto Y, Nishio K, Tamura T, Matsuda T, and Saijo N (1992). Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 84:113-118.
19. Kreipe H, Aim P, Olsson H, Hauberg M, Fischer L, and Parwaresch R (1993). Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. Am J Pathol 142:651-657.
20. Kreisholt J, Sorensen M, Jensen PB, Nielsen BS, Andersen CB, and Sehested M (1998). Immunohistochemical detection of DNA topoisomerase IIα, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer. Br J Cancer 77:1469-1473.
21. Lang AJ, Mirski SE, Cummings HJ, Yu Q, Gerlach JH, and Cole SPC (1998). Structural organization of the human TOP2A and TOP2B genes. Gene 221:255-266.
22. Larsen AK and Skladanowski A (1998). Cellular resistance to topoisomerase-targeted drugs: From drug uptake to cell death. Biochim Biophys Acta 1400:257-274.
23. Meczes EL, Marsh KL, Fisher LM, Rogers MP, and Austin CA (1997). Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2β construct allows the study of topoisomerase IIβ inhibitors in yeast. Cancer Chemother Pharmacol 39:367-375.
24. Mirski SEL and Cole SPC (1997). Multidrug resistance in small cell lung cancer. In: Bernai SD, editor. Drug Resistance in Oncology. New York: Marcel Dekker, 27-75.
25. Mirski SEL, Evans CD, Almquist KC, Slovak ML, and Cole SPC (1993). Altered topoisomerase IIα in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res 53:4866-4873.
26. Ng SW, Liu Y, and Schnipper LE (1997). Cloning and characterization of the 5′-flanking sequence for the human DNA topoisomerase IIβ gene. Gene 203:113-119.
27. Nitiss JL and Beck WT (1996). Antitopoisomerase drug action and resistance. Eur J Cancer 32A:958-966.
28. Ohashi Y, Sasano H, Yamaki H, Shizawa S, Kikuchi A, Shineha R, Akaishi T, Satomi S, and Nagura H (1999). Topoisomerase IIα expression in esophageal squamous cell carcinoma. Anticancer Res 19:1873-1880.
29. Perrin D, van Hille B, and Hill BT (1998). Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II-interacting agents. Biochem Pharmacol 56:503-507.
30. Rudolph P, MacGrogan G, Bonichon F, Frahm SO, de Mascarel I, Trojani M, Durand M, Avril A, Coindre JM, and Parwaresch R (1999). Prognostic significance of Ki-67 and topoisomerase IIα expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Breast Cancer Res Treat 55:61-71.
31. Sambrook J, Fritsch EF, and Maniatis T (1989). Molecular Cloning: A Laboratory Manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
32. Sandri MI, Hochhauser D, Ayton P, Camplejohn RC, Whitehouse R, Turley H, Gatter K, Hickson ID, and Harris AL (1996). Differential expression of the topoisomerase IIα and β genes in human breast cancers. Br J Cancer 73:1518-1524.
33. Sehested M, Wessel I, Jensen LH, Holm B, Oliveri RS, Kenwrick S, Creighton AM, Nitiss JL, and Jensen PB (1998). Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: A Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Cancer Res 58:1460-1468.
34. Syahruddin E, Oguri T, Takahashi T, Isobe T, Fujiwara Y, and Yamakido M (1998). Differential expression of DNA topoisomerase IIα and IIβ genes between small cell and non-small cell lung cancer. Jpn J Cancer Res 89:855-861.
35. Turley H, Comley M, Houlbrook S, Nozaki N, Kikuchi A, Hickson ID, Gatter K, and Harris AL (1997). The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer 75: 1340-1346.
36. Wang JC (1996). DNA topoisomerases. Annu Rev Biochem 65:635-692.
37. Webb CF, Eneff KL, and Drake FH (1993). A topoisomerase II-like protein is part of an inducible DNA-binding protein complex that binds 5′ of an immunoglobulin promoter. Nucleic Acids Res 21:4363-4368.
38. Wessel I, Jensen LH, Jensen PB, Falck J, Rose A, Roerth M, Nitiss JL, and Sehested M (1999). Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the a isoform. Cancer Res 59:3442-3450.
39. Young LC, Campling BG, Voskoglou-Nomikos T, Cole SPC, Deeley RG, and Gerlach JH (1999). Expression of multidrug resistance protein-related genes in lung cancer: Correlation with drug response. Clin Cancer Res 5:673-680.